Ipamorelin / CJC-1295
Ipamorelin / CJC-1295
The Ipamorelin and CJC-1295 No DAC combination is a cutting-edge approach to enhancing growth hormone (GH) secretion, offering a synergistic solution to promote a youthful biological state. This powerful blend merges Ipamorelin’s selective GH secretagogue properties with the modified growth hormone-releasing factor (GRF) analog, CJC-1295 No DAC, to stimulate natural, pulsatile GH release from the anterior pituitary, closely mimicking the body’s own rhythms for optimal results.
Ipamorelin is notable for its precision, binding to the ghrelin receptor with high specificity to trigger GH release without elevating cortisol or acetylcholine levels, common drawbacks of other GH secretagogues. This targeted action supports the anabolic and rejuvenating benefits of GH while minimizing side effects.
CJC-1295 No DAC extends the activity of endogenous GRF through modifications that resist enzymatic breakdown, resulting in prolonged GH release. By omitting the Drug Affinity Complex (DAC), this formulation ensures a GH release pattern that aligns closely with natural processes, amplifying Ipamorelin’s effects.
This combined formulation simplifies GH therapy, reducing complexity and cost while delivering a balanced, robust GH release. It supports muscle growth, fat loss, faster recovery, and comprehensive anti-aging benefits, making it an innovative option for biohacking and age management.